MYD88 and rheumatoid arthritis: The investigation of rheumatoid arthritis (RA) revealed that Sinomenine markedly diminished the inflammatory reaction of fibroblast-like synoviocytes (FLS) while also decreasing the levels of MyD88 and TRAF6 by blocking the TLR4/MyD88/NF-κB signaling pathway, thereby offering molecular support for the treatment of RA (190).